Bio-Thera and Avalon Pharma Sign MENA Deal for BAT2406, Proposed Dupixent Biosimilar
China’s Bio-Thera Solutions and Saudi Arabia-based Avalon Pharma have entered into commercialization and license agreements for BAT2406, a proposed biosimilar to Dupixent® (dupilumab), covering Saudi Arabia and the broader Middle East and North Africa…
Henlius Expands Sandoz Partnership in Up to $322 Million Biosimilars Deal
Shanghai Henlius Biotech, Inc. (“Henlius”) has significantly expanded its partnership with Sandoz, entering a strategic collaboration covering up to 10 monoclonal antibody (mAb) and antibody-drug conjugate (ADC) biosimilar candidates in a…